Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers

Kasherman, Lawrence; Liu, Shiru; Karakasis, Katherine; Lheureux, Stéphanie

doi:10.3390/cancers14051122

Cited by 6 publications

(5 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 21 A high degree of tumor angiogenesis has been shown to correlate with poor survival in ovarian cancer patients. 10 , 22 Thus, it is crucial to regulate tumor angiogenesis, including both angiogenesis-related key factors and downstream effectors, to rebuild the tumor vessel microenvironment, which can facilitate tumor growth and influence treatment.…”

Section: Update On Angiogenesis Mechanisms In Gynecological Cancersmentioning

confidence: 99%

“…Another small molecular angiogenesis inhibitor, lenvatinib, has also obtained approval, in combination with pembrozliumab, for subsequent-line treatment of advanced endometrial cancer. 10 Table 1 presents more information about currently-approved drugs and their indications/clinical applications in gynecological cancers.…”

Section: Clinical Practice Involving Vessel Regulationmentioning

confidence: 99%

“…7,9 Therefore, the regulation of tumor vessel microenvironment deserves careful attention, and exploring therapeutic strategies against gynecological cancers with blood vessel regulation as an entry point holds great potential. Although anti-angiogenic drugs have already demonstrated clinical efficacy in gynecological cancers, 10 the full potential of tumor blood vessel-associated therapeutic strategies has yet to be fulfilled. Inspiringly, the application of nano-delivery platforms has offered great inspiration for more efficient drug delivery, as well as more delicate tumor vessel regulation and microenvironment rebuild.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms

Shan¹,

Fei²,

Zhao³

et al. 2023

IJN

View full text Add to dashboard Cite

Angiogenesis is an essential mechanism for the progression of gynecological cancers. Although approved anti-angiogenic drugs have demonstrated clinical efficacy in treating gynecological cancers, the full potential of therapeutic strategies based on tumor blood vessels has not yet been realized. This review summarizes the latest angiogenesis mechanisms involved in the progression of gynecological cancers and discusses the current clinical practice of approved anti-angiogenic drugs and related clinical trials. Given the close relationship between gynecological cancers and blood vessels, we highlight more delicate strategies for regulating tumor vessels, including wise drug combinations and smart nano-delivery platforms to achieve highly efficient drug delivery and overall vessel microenvironment regulation. We also address current challenges and future opportunities in this field. We aim to generate interest in therapeutic strategies that target blood vessels as a key entry point and offer new potential and inspiration for combating gynecological cancers.

show abstract

Section: Update On Angiogenesis Mechanisms In Gynecological Cancersmentioning

confidence: 99%

Section: Clinical Practice Involving Vessel Regulationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms

Shan¹,

Fei²,

Zhao³

et al. 2023

IJN

View full text Add to dashboard Cite

show abstract

“…Angiogenesis refers to developing new blood vessels from existing capillaries or postcapillary veins [ 119 , 120 ]. Generally, the whole process of angiogenesis occured in tissues is coordinated by angiogenic and vasopressor factors [ 121 , 122 ]. Under external factors, internal genetic mutations, and tumorigenesis, the angiogenic factors are overactivated, while the vasopressor is suppressed.…”

Section: The Roles Of Texs In Angiogenesismentioning

confidence: 99%

Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma

2022

View full text Add to dashboard Cite

Small extracellular vesicles (SEVs) are extracellular vesicles containing DNA, RNA, and proteins and are involved in intercellular communication and function, playing an essential role in the growth and metastasis of tumors. SEVs are present in various body fluids and can be isolated and extracted from blood, urine, and cerebrospinal fluid. Under both physiological and pathological conditions, SEVs can be released by some cells, such as immune, stem, and tumor cells, in a cytosolic manner. SEVs secreted by tumor cells are called tumor-derived exosomes (TEXs) because of their origin in the corresponding parent cells. Glioma is the most common intracranial tumor, accounting for approximately half of the primary intracranial tumors, and is characterized by insidious onset, high morbidity, and high mortality rate. Complete removal of tumor tissues by surgery is difficult. Chemotherapy can improve the survival quality of patients to a certain extent; however, gliomas are prone to chemoresistance, which seriously affects the prognosis of patients. In recent years, TEXs have played a vital role in the occurrence, development, associated immune response, chemotherapy resistance, radiation therapy resistance, and metastasis of glioma. This article reviews the role of TEXs in glioma progression, drug resistance, and clinical diagnosis.

show abstract

“…BAP31 has been further reported to regulate migration and invasion in ovarian ( 26 ), cervical ( 22 ), and lung cancers ( 27 ). Cancer metastasis arises through multistep pathways, and the induction of angiogenesis is shown to be a rate-limiting step in the process of tumor metastasis ( 28 , 29 ). However, little is known about whether the aberrant expression of BAP31 in CRC affects the biological functions of surrounding tissues in the TME.…”

Section: Introductionmentioning

confidence: 99%

The BAP31/miR-181a-5p/RECK axis promotes angiogenesis in colorectal cancer via fibroblast activation

Zhang

Wang²,

Li³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundB-cell receptor–associated protein 31 (BAP31) has been recognized as a tumor-associated protein and has largely been shown to promote metastasis in a variety of cancers. Cancer metastasis arises through multistep pathways, and the induction of angiogenesis is shown to be a rate-limiting step in the process of tumor metastasis.Methods and resultsThis study explored the effect of BAP31 on colorectal cancer (CRC) angiogenesis by regulating the tumor microenvironment. First, exosomes from BAP31-regulated CRCs affected the transition of normal fibroblasts to proangiogenic cancer-associated fibroblasts (CAFs) in vivo and in vitro. Next, microRNA sequencing was performed to analyze the microRNA expression profile of exosomes secreted from BAP31- overexpressing CRCs. The results indicated that the expression of BAP31 in CRCs significantly altered the levels of exosomal microRNAs, such as miR-181a- 5p. Meanwhile, an in vitro tube formation assay showed that fibroblasts with high levels of miR-181a-5p significantly promoted endothelial cell angiogenesis. Critically, we first identified that miR-181a-5p directly targeted the 3'-untranslated region (3′UTR) of reversion-inducing cysteine-rich protein with kazal motifs (RECK) using the dual-luciferase activity assay, which drove fibroblast transformation into proangiogenic CAFs by upregulating matrix metalloproteinase-9 (MMP-9) and phosphorylation of mothers against decapentaplegic homolog 2/Mothers against decapentaplegic homolog 3 (Smad2/3). ConclusionExosomes from BAP31-overexpressing/BAP31-knockdown CRCs are found to manipulate the transition of fibroblasts into proangiogenic CAFs by the miR-181a-5p/RECK axis.

show abstract

Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers

Cited by 6 publications

References 129 publications

Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms

Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms

Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma

The BAP31/miR-181a-5p/RECK axis promotes angiogenesis in colorectal cancer via fibroblast activation

Contact Info

Product

Resources

About